Title: Global Health Innovation Act of 2017
Policy area: International Affairs

Summary:
Global Health Innovation Act of 2017
This bill directs the Administrator of the U.S. Agency for International Development (USAID) to report to Congress, annually for four years, on the development and use of global health innovations in USAID programs, projects, and activities.

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1660 Introduced in House (IH)]

<DOC>






115th CONGRESS
  1st Session
                                H. R. 1660

      To direct the Administrator of the United States Agency for 
    International Development to submit to Congress a report on the 
   development and use of global health innovations in the programs, 
                projects, and activities of the Agency.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 21, 2017

 Mr. Sires (for himself, Mr. Diaz-Balart, Mr. Connolly, Mr. Engel, Mr. 
Sherman, Mr. Cicilline, Mr. Keating, Ms. Ros-Lehtinen, Mr. Donovan, and 
   Mr. Smith of New Jersey) introduced the following bill; which was 
              referred to the Committee on Foreign Affairs

_______________________________________________________________________

                                 A BILL


 
      To direct the Administrator of the United States Agency for 
    International Development to submit to Congress a report on the 
   development and use of global health innovations in the programs, 
                projects, and activities of the Agency.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Global Health Innovation Act of 
2017''.

SEC. 2. ANNUAL REPORT.

    (a) In General.--Not later than 180 days after the date of the 
enactment of this Act, and annually thereafter for a period of 4 years, 
the Administrator of the United States Agency for International 
Development shall submit to Congress a report on the development and 
use of global health innovations in the programs, projects, and 
activities of the Agency.
    (b) Matters To Be Included.--The report required by subsection (a) 
shall include the following:
            (1) A description of--
                    (A) the extent to which global health innovations 
                described in subsection (a) include drugs, diagnostics, 
                devices, vaccines, electronic and mobile health 
                technologies, and related behavior change and service 
                delivery innovations;
                    (B) how innovation has advanced the Agency's 
                commitments to achieving an HIV/AIDS-free generation, 
                ending preventable child and maternal deaths, and 
                protecting communities from infectious diseases, as 
                well as furthered by the Global Health Strategic 
                Framework;
                    (C) how goals are set for health product 
                development in relation to the Agency's health-related 
                goals and how progress and impact are measured towards 
                those goals;
                    (D) how the Agency's investments in innovation 
                relate to its stated goals; and
                    (E) progress made towards health product 
                development goals.
            (2) How the Agency, both independently and with partners, 
        donors, and public-private partnerships, is--
                    (A) leveraging United States investments to achieve 
                greater impact in health innovation;
                    (B) engaging in activities to develop, advance, and 
                introduce affordable, available, and appropriate global 
                health products; and
                    (C) scaling up appropriate health innovations in 
                the development pipeline.
            (3) A description of collaboration and coordination with 
        other Federal departments and agencies, including the Centers 
        for Disease Control and Prevention, in support of global health 
        product development, including a description of how the Agency 
        is working to ensure critical gaps in product development for 
        global health are being filled.
            (4) A description of how the Agency is coordinating and 
        aligning global health innovation activities between the Global 
        Development Lab, the Center for Accelerating Innovation and 
        Impact, and the Bureau for Global Health.
                                 <all>